Kinaxo Receives Grant for Drug Efficiency Study
- Posted on 27 February 2009
Kinaxo Biotechnologies has been awarded a grant by the Bavarian Research Foundation to expand applications for its quantitative phosphoproteomics platform to contribute to a drug efficacy study.
The company has joined an interdisciplinary collaboration with Priaxon, Genomatix Software, the Technical University Munich and the University Hospital “Rechts der Isar†.
The aim of the collaboration is to establish tools for identifying tumor-relevant signal transduction pathways and therapeutic targets. Kinaxo will use its quantitative phosphoproteomics approach to evaluate the efficacy of established and new compounds for pancreatic cancer treatment. It will also try to identify predictive biomarkers that facilitate the design and monitoring of individualized therapeutic strategies.
